Skip to navigation Skip to content



Public Comment Period Open: The Institute for Clinical and Economic Review Seeks Comments on Review of MS Disease Modifying Therapies

July 1, 2016

On July 1, the Institute for Clinical and Economic Review (ICER) released its draft scope to review MS disease modifying therapies used to treat relapsing-remitting MS. Public comments are due by July 15. 

ICER assesses the value of medications by considering price, how well a medication works compared to others, quality adjusted life years (QALYs) and other cost-effectiveness factors. Different insurers may use ICER recommendations to develop their formularies, so ICER recommendations could potentially limit access to MS medications. 

The National MS Society will submit comments and anticipates that the MS Coalition, a group of nine organizations serving people with MS, will also submit comments. 

Individuals may also submit comments. ICER plans to release a draft evidence report around November 22nd, which will open another public comment period. This will be followed by a public meeting to review the report in February 2017.

To review the draft scope:

To submit comments, send by email to:
All comments must be submitted following the below formatting specifications: 
•    Times New Roman, 12-point font size
•    Three pages maximum (excluding references)
•    Word document (no PDFs)
•    Electronic copy only

About Multiple Sclerosis

Multiple sclerosis is an unpredictable, often disabling disease of the central nervous system that disrupts the flow of information within the brain, and between the brain and body. Symptoms range from numbness and tingling to blindness and paralysis. The progress, severity and specific symptoms of MS in any one person cannot yet be predicted, but advances in research and treatment are leading to better understanding and moving us closer to a world free of MS. Most people with MS are diagnosed between the ages of 20 and 50, with at least two to three times more women than men being diagnosed with the disease. MS affects more than 2.3 million people worldwide.


© 2020 The National Multiple Sclerosis Society is a tax exempt 501(c)3 nonprofit organization and our Identification Number (EIN) is 13-5661935.